PT Hepatitis Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

What are characteristics of hepatitis A infection?

A

self limiting illness, acute and rarely lead to chronic infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

3 stage of hepatitis A infection?

A

Incubation (14-50 days)
acute hepatitis
convalescence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How to dx hepatitis A infection?

A

1) IgM antibody HAV (anti-HAV) detectable in the serum 5–10 days before the onset
of symptoms
2) Once the infection clears, the IgM antibody is replaced by IgG antibodies during a 2 to 6month period (lifelong protective immunity against subsequent infection
3) Elevated aminotransferases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are post-exposure prophylaxis for HAV?

A
  • Immune globulin can be given at a dose of 0.1 mL/kg intramuscularly within 2 weeks of exposure.
  • HAV vaccine is recommended in patients 12 months to 40 years
    old who are otherwise healthy.
  • HAV vaccine with or without concurrent immune globulin in patients older than 40 years.
  • Both the vaccine and immune globulin in patients 12 months and older who are immunocompromised or who have chronic
    liver disease.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which hepatitis virus affect most patient and commonly spread worldwide?

A

Hepatitis B Virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Transmission routes of HBV?

A
  • Parenteral: iv drug abuse, needlestick, ear or body piercing.
  • Bodily fluids: saliva, semen, vaginal fluid.
  • Sexual contact: heterosexual and homosexual.
  • Perinatal: mother to child at birth.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What the most effective strategy in preventing complications of HBV infections?

A

Vaccination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is initial therapy of chronic HBV?

A

Entecavir

Tenofovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Monitoring for efficacy should be based on the following responses?

A
  • Primary nonresponse: decrease in HBV DNA of less than 100 copies/mL after at least 24 weeks of therapy. alternative treatment.
  • Response should be assessed by reductions in HBV DNA for HBeAg‐negative patients.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dose for Peg‐α‐2a (Pegasys)?

A

180 mcg SC once weekly for 48 weeks

same duration for HBeAg‐negative and positive disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Adverse effect of pegylated interferon?

A

Bone marrow suppression
CNS depression
Exacerbate underlying autoimmune disorder
Thyroid dysfunction
(Manufacturers give recommendations for dose reductions in patients who
develop bone marrow suppression and depression while on therapy.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is dose for entecavir in tx chronic HBV infection?

A
  • 0.5 mg orally once daily for patients > 16 years and nucleoside naive;
  • 1 mg orally once daily for patients > 16 years with HBV viremia while receiving lamivudine or in lamivudine resistant
    HBV
  • Dose adjustments required for renal impairment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is Doses of HBV immune globulin in postexposure prophylaxis for HBV

A

0.06 mL/kg intramuscularly and must be given within 7 days of exposure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Patient populations requiring postexposure prophylaxis for HBV?

A

a) Perinatal transmission
(1) Children born to HBsAg‐positive mothers should receive the first dose of the three dose vaccine series plus
HBV immune globulin within 12 hours of birth.
(2) Children born to mothers with unknown HBsAg status (but suspected) should receive the first dose of the
three‐dose vaccine series within 12 hours of birth; testing should be performed on the child, and if positive,
HBV immune globulin should be administered within 1 week.
(3) Infants weighing less than 2 kg at birth whose mothers are documented as HBsAg negative should receive
the first dose of the vaccine series 1 month after birth or at hospital discharge, whichever comes first.
(b) Sexual contact or household contact with an infected person: Should receive HBV immune globulin plus
vaccine series if exposed person is previously unvaccinated
(c) Sexual contact or household contact with an HBV carrier: Should receive vaccine series if exposed person
was previously unvaccinated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What major cause of chronic liver disease infection (71 millions worldwide)?

A

HCV infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Primary goal of HCV treatment?

A

To cure the infection i.e., to achieve a

sustained virological response (SVR).

17
Q

What laboratory‐based immunoassay to dx HCV?

A

anti‐HCV antibody (rapid diagnostic test) and HCV ribonucleic acid
(RNA) or hepatitis C core antigen (HCVcAg)

18
Q

What is is the preferred non‐invasive imaging modality for diagnosis of liver fibrosis and cirrhosis in hepatitis C?

A
Transient elastrography (TE)
If TE is not
available, ultrasound abdomen is an alternative modality
19
Q

HCV‐ Pretreatment Assessment?

A
  • Assess cirrhotic status.
  • Identify presence of co‐morbidity & perform baseline
    investigations :
    *full blood count & INR (for all cirrhotic patients)
    *liver function test (LFT) including AST
    *serum creatinine
    *HIV & hepatitis B surface antigen screening
    *APRI and/or FIB‐4 score
  • Assessment of concomitant medication (30 ‐ 44% of patients on
    DAAs are at risk of clinically significant DDIs).
  • counsel for female patient and partner of male patient to avoid pregnancy during and six months after completion of treatment.
20
Q

What factor can increase the risk of developing cirrhosis in HCV?

A

Alcohol use, HBV or HIV coinfection and immunosuppression due to any cause

21
Q

In patients with hepatitis C and decompensated cirrhosis, what combination of direct‐acting antivirals may be used for 12 weeks?

A
  • sofosbuvir (SOF) + daclatasvir (DCV) + ribavirin (RBV)
  • sofosbuvir/velpatasvir (SOF/VEL) + RBV
  • sofosbuvir/ledipasvir + RBV (for genotype 1 and 4)
22
Q

In patients with hepatitis C and decompensated cirrhosis with genotype 2 or 3 and are ribavirin ineligible, SOF + DCV and SOF/VEL may be given for 24 weeks.

A

Baca je

23
Q

Monitoring in HCV treatment?

A

• Routine laboratory monitoring (LFT, serum creatinine) shall be limited at week 4 & 12 weeks post‐DAAs treatment.
• More frequent monitoring e.g., FBC for drug‐related adverse events is necessary for those treated with RBV.
• In patients who need RBV, the dose should be adjusted downward by 200 mg in decrement if the hemoglobin level drops below 10 g/dL. RBV administration should be
stopped if the level drops below 8.5 g/dL.
• Patients with acute HCV should be monitored for six months for spontaneous viral clearance before initiating treatment. Those who achieve spontaneous clearance should not be treated with antiviral.